Cargando…

An assessment of the strategy and status of COVID-19 vaccination in India

The COVID-19 disease continues to cause devastation for almost 3 years of its identification. India is one of the leading countries to set clinical trials, production, and administration of COVID-19 vaccination. Recent COVID-19 vaccine tracker record suggests that 12 vaccines are approved in India,...

Descripción completa

Detalles Bibliográficos
Autores principales: Gupta, Sneh Lata, Goswami, Surbhi, Anand, Ananya, Naman, Namrata, Kumari, Priya, Sharma, Priyanka, Jaiswal, Rishi K.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10089693/
https://www.ncbi.nlm.nih.gov/pubmed/37041424
http://dx.doi.org/10.1007/s12026-023-09373-5
_version_ 1785022814240112640
author Gupta, Sneh Lata
Goswami, Surbhi
Anand, Ananya
Naman, Namrata
Kumari, Priya
Sharma, Priyanka
Jaiswal, Rishi K.
author_facet Gupta, Sneh Lata
Goswami, Surbhi
Anand, Ananya
Naman, Namrata
Kumari, Priya
Sharma, Priyanka
Jaiswal, Rishi K.
author_sort Gupta, Sneh Lata
collection PubMed
description The COVID-19 disease continues to cause devastation for almost 3 years of its identification. India is one of the leading countries to set clinical trials, production, and administration of COVID-19 vaccination. Recent COVID-19 vaccine tracker record suggests that 12 vaccines are approved in India, including protein subunit, RNA/DNA, non-replicating viral vector, and inactivated vaccine. Along with that 16 more vaccines are undergoing clinical trials to counter COVID-19. The availability of different vaccines gives alternate and broad perspectives to fight against viral immune resistance and, thus, viruses escaping the immune system by mutations. Using the recently published literature on the Indian vaccine and clinical trial sites, we have reviewed the development, clinical evaluation, and registration of vaccines trial used in India against COVID-19. Moreover, we have also summarized the status of all approved vaccines in India, their associated registered clinical trials, manufacturing, efficacy, and their related safety and immunogenicity profile.
format Online
Article
Text
id pubmed-10089693
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Springer US
record_format MEDLINE/PubMed
spelling pubmed-100896932023-04-12 An assessment of the strategy and status of COVID-19 vaccination in India Gupta, Sneh Lata Goswami, Surbhi Anand, Ananya Naman, Namrata Kumari, Priya Sharma, Priyanka Jaiswal, Rishi K. Immunol Res Review The COVID-19 disease continues to cause devastation for almost 3 years of its identification. India is one of the leading countries to set clinical trials, production, and administration of COVID-19 vaccination. Recent COVID-19 vaccine tracker record suggests that 12 vaccines are approved in India, including protein subunit, RNA/DNA, non-replicating viral vector, and inactivated vaccine. Along with that 16 more vaccines are undergoing clinical trials to counter COVID-19. The availability of different vaccines gives alternate and broad perspectives to fight against viral immune resistance and, thus, viruses escaping the immune system by mutations. Using the recently published literature on the Indian vaccine and clinical trial sites, we have reviewed the development, clinical evaluation, and registration of vaccines trial used in India against COVID-19. Moreover, we have also summarized the status of all approved vaccines in India, their associated registered clinical trials, manufacturing, efficacy, and their related safety and immunogenicity profile. Springer US 2023-04-11 /pmc/articles/PMC10089693/ /pubmed/37041424 http://dx.doi.org/10.1007/s12026-023-09373-5 Text en © This is a U.S. Government work and not under copyright protection in the US; foreign copyright protection may apply 2023 This article is made available via the PMC Open Access Subset for unrestricted research re-use and secondary analysis in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the World Health Organization (WHO) declaration of COVID-19 as a global pandemic.
spellingShingle Review
Gupta, Sneh Lata
Goswami, Surbhi
Anand, Ananya
Naman, Namrata
Kumari, Priya
Sharma, Priyanka
Jaiswal, Rishi K.
An assessment of the strategy and status of COVID-19 vaccination in India
title An assessment of the strategy and status of COVID-19 vaccination in India
title_full An assessment of the strategy and status of COVID-19 vaccination in India
title_fullStr An assessment of the strategy and status of COVID-19 vaccination in India
title_full_unstemmed An assessment of the strategy and status of COVID-19 vaccination in India
title_short An assessment of the strategy and status of COVID-19 vaccination in India
title_sort assessment of the strategy and status of covid-19 vaccination in india
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10089693/
https://www.ncbi.nlm.nih.gov/pubmed/37041424
http://dx.doi.org/10.1007/s12026-023-09373-5
work_keys_str_mv AT guptasnehlata anassessmentofthestrategyandstatusofcovid19vaccinationinindia
AT goswamisurbhi anassessmentofthestrategyandstatusofcovid19vaccinationinindia
AT anandananya anassessmentofthestrategyandstatusofcovid19vaccinationinindia
AT namannamrata anassessmentofthestrategyandstatusofcovid19vaccinationinindia
AT kumaripriya anassessmentofthestrategyandstatusofcovid19vaccinationinindia
AT sharmapriyanka anassessmentofthestrategyandstatusofcovid19vaccinationinindia
AT jaiswalrishik anassessmentofthestrategyandstatusofcovid19vaccinationinindia
AT guptasnehlata assessmentofthestrategyandstatusofcovid19vaccinationinindia
AT goswamisurbhi assessmentofthestrategyandstatusofcovid19vaccinationinindia
AT anandananya assessmentofthestrategyandstatusofcovid19vaccinationinindia
AT namannamrata assessmentofthestrategyandstatusofcovid19vaccinationinindia
AT kumaripriya assessmentofthestrategyandstatusofcovid19vaccinationinindia
AT sharmapriyanka assessmentofthestrategyandstatusofcovid19vaccinationinindia
AT jaiswalrishik assessmentofthestrategyandstatusofcovid19vaccinationinindia